# Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Source: https://onco.cc/trials/nct04614103/  
OnCo record `nct04614103` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of LN-145 in non-small-cell lung cancer, run by Iovance Biotherapeutics, Inc., now recruiting.

## Summary

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer is a phase 2 interventional study registered as NCT04614103 by Iovance Biotherapeutics, Inc., with 170 participants planned, started 2021-05-07 and due to reach its primary completion in 2030-12. Interventions recorded: LN-145.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04614103
- Phase: 2
- Setting: A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer
- Sponsor: Iovance Biotherapeutics, Inc.
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT04614103: https://clinicaltrials.gov/study/NCT04614103

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Iovance Biotherapeutics](https://onco.cc/companies/iovance/)

---
JSON: https://onco.cc/api/v1/entities/nct04614103.json